Literature DB >> 3936114

Radiosensitization of human fibroblasts by 3-aminobenzamide: an inhibitor of poly(ADP-ribosylation).

P Thraves, K L Mossman, T Brennan, A Dritschilo.   

Abstract

The poly(ADP-ribose) synthetase inhibitor 3-aminobenzamide (3AB) increases the radiosensitivity of normal human fibroblasts in tissue culture in a dose-dependent manner at noncytotoxic concentrations. 3AB was also found to inhibit the repair of potentially lethal damage as well as the recovery occurring when radiation was delivered as fractionated vs single exposures. However, repair as measured by an increased survival when radiation is delivered at low dose rate compared to high dose rate was not effected by 3AB administration.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3936114

Source DB:  PubMed          Journal:  Radiat Res        ISSN： 0033-7587            Impact factor:   2.841


  5 in total

1.  INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin.

Authors:  Kathryn A Mason; David Valdecanas; Nancy R Hunter; Luka Milas
Journal:  Invest New Drugs       Date:  2007-07-13       Impact factor: 3.850

2.  Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.

Authors:  Francesco Sabbatino; Celeste Fusciello; Domenico Somma; Roberto Pacelli; Ravin Poudel; David Pepin; Antonio Leonardi; Chiara Carlomagno; Giuseppina Della Vittoria Scarpati; Soldano Ferrone; Stefano Pepe
Journal:  Cytometry A       Date:  2014-09-02       Impact factor: 4.355

Review 3.  Iron, radiation, and cancer.

Authors:  R G Stevens; D R Kalkwarf
Journal:  Environ Health Perspect       Date:  1990-07       Impact factor: 9.031

4.  PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors.

Authors:  Valentina Perini; Michelle Schacke; Pablo Liddle; Salomé Vilchez-Larrea; Deborah J Keszenman; Laura Lafon-Hughes
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

5.  Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck.

Authors:  E Kjellén; J Wennerberg; R Pero
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.